Working… Menu

Scopolamine Treatment for Patients With Organophosphate Poisoning

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00389259
Recruitment Status : Withdrawn
First Posted : October 18, 2006
Last Update Posted : April 5, 2011
Israeli MOH
International Diabetes Federation
Information provided by:
Assaf-Harofeh Medical Center

Brief Summary:

Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a common cause of death among people who commit suicide in developing countries. OPs poisoning also frequently occurs after accidental exposure to agricultural OPs and in children as a result of unintentional ingestion.

The use of competitive inhibitors of acetylcholine other than atropine for patient with organophosphate (OP) poisoning is controversial. Because scopolamines' ability to cross the blood brain barrier is better than atropine, it has been suggested that scopolamine should be used OP poisoned patients who have central nervous system (CNS) manifestations. However there is controversy regarding its potential benefit in the treatment of organophosphate poisoning in humans. To the best of our knowledge there are no randomised controlled studies on the use of scopolamine in humans. This prospective randomised controlled study is aimed to determine whether adding scopolamine to the standard treatment of atropine and oximes in patients with CNS symptoms of OP poisoning improve the outcome.

Condition or disease Intervention/treatment Phase
Neurotoxicity Syndromes Drug: Placebo Not Applicable

Detailed Description:
Objective: to determine whether adding scopolamine to the standard treatment of atropine and oximes improve the outcome of patients with OP poisoning and CNS manifestations. Design: A multi-center, randomized, double blind, placebo controlled study. Setting: Emergency Departments & Intensive Care Units in Israel. Participants: Patients 2 -60 years old with acute OP poisoning and CNS manifestations. Interventions: In addition to standard treatment with atropine and obidoxime, eligible patients will be randomly assigned to one of two treatment groups, scopolamine group, and placebo group (both given in the same volume). Scopolamine will be given IM or IV in a dose of 0.25mg for adults and 0.006mg/kg for children every 4 hours. At least three doses of scopolamine (or placebo) will be given. The medical staff will be blinded to the treatment given. Main outcome measures: Improvement in neurological status, duration of seizures and number of days on ventilator. Data analysis: The main outcome measures, will be compared using the Student's t-test or the Mann-Whitney tests as appropriate. The *2 or Fisher Exact tests, as appropriate, will be used for comparisons of categorical variables. We will use multiple logistic regression to examine the extent to which variables predict success or failure of the treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Scopolamine Treatment for Patients With Organophosphate Poisoning - a Randomized, Double Blind, Placebo-Controlled Study.
Study Start Date : October 2007
Estimated Study Completion Date : December 2009

Arm Intervention/treatment
Experimental: A
IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
Drug: Placebo
IV placebo q4h

Placebo Comparator: B
IV Look alike drug Q 4h
Drug: Placebo
IV placebo q4h

Primary Outcome Measures :
  1. Improvement in neurological status as measured by the Glasgow Coma Scale [ Time Frame: 1 week ]
  2. Duration of seizures. [ Time Frame: 1 week ]
  3. Number of days on ventilator [ Time Frame: 1 week ]

Secondary Outcome Measures :
  1. Total cumulative dose of atropine [ Time Frame: 1 week ]
  2. Need for benzodiazepines [ Time Frame: 1 week ]
  3. Number of days in the ICU [ Time Frame: 2 weeks ]
  4. Adverse effects and complications [ Time Frame: 2 weeks ]
  5. Neurological assessment at discharge [ Time Frame: 2 weeks ]
  6. Neurological assessment 3 month after the exposure [ Time Frame: 3 month ]
  7. Neuro-cognitive assessment at 3 month [ Time Frame: 3 month ]
  8. Survival at 24 hours [ Time Frame: 24 hours ]
  9. Survival to discharge [ Time Frame: 4 weeks ]
  10. Number of days in hospital [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 2- 60 years
  • At least two of the following three criteria:

    • Known exposure to an organophosphate or carbamate insecticide in the last 72 hours.
    • Symptoms and signs typical to organophosphate poisoning involving at least two systems (gastrointestinal, respiratory, skin, eyes,) See appendix
    • Low levels of plasma butyrylcholinesterase (less than 50% of the lower normal range )
  • CNS involvement in the first 72 hours after exposure: determined by finding at least one of the following major criteria or at least two of the minor criteria

Major criteria for CNS involvement:

  • Seizures
  • Extrapyramidal or Parkinson like symptoms
  • Decreased level of consciousness (GCS< 12)

Minor criteria for CNS involvement:

  • GCS 14-12
  • Confusion
  • Hallucinations

Exclusion Criteria:

  • Hypersensitivity to scopolamine
  • Glaucoma, narrow-angle (angle-closure)
  • Tachyarrhythmias, congestive heart failure
  • Obstructive gastrointestinal disease
  • Myasthenia Gravis
  • Reflux esophagitis
  • Ulcerative colitis
  • Known obstructive uropathy
  • Pregnancy
  • Patient or legal guardian unable to give informed consent (see comment under ethics)
  • Severe co-morbidity (multi-trauma, advanced cancer, etc)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00389259

Layout table for location information
Rambam Hospital
Haifa, Israel
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Israeli MOH
International Diabetes Federation
Layout table for investigator information
Principal Investigator: Eran Kozer, MD Assaf-Harofeh Medical Center
Layout table for additonal information Identifier: NCT00389259    
Other Study ID Numbers: 70/04*1
First Posted: October 18, 2006    Key Record Dates
Last Update Posted: April 5, 2011
Last Verified: March 2010
Keywords provided by Assaf-Harofeh Medical Center:
randomized control study
Organophosphate or carbamate intoxication
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurotoxicity Syndromes
Organophosphate Poisoning
Chemically-Induced Disorders
Nervous System Diseases